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Abstract
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Unresolved inflammation is a major contributor to the development of heart failure following
myocardial infarction (MI). Pro-resolving lipid mediators, such as resolvins (e.g. RvD1), are
biosynthesized endogenously. The role of RvD1 in resolving post-MI inflammation has not been
elucidated due to its unstable nature. Here, we have tested the role for two forms of RvD1, after
incorporation into liposomes (Lipo-RvD1) and its free acid form (RvD1) in left ventricle (LV) and
splenic remodeling post-MI. 8 to 12-week old male, C57BL/6J-mice were subjected to coronary
artery ligation and Lipo-RvD1 or RvD1 (3µg/kg/day) was injected 3 hr post-MI for day (d)1 or
until d5. No-MI mice and saline-injected MI mice served as controls. RvD1 injected groups
showed improved fractional shortening post-MI; preserving transient changes in the splenic
reservoir compared to MI-saline. RvD1-groups showed an early exit of neutrophils from LV and
spleen at d5 post-MI with an increased expression of lipoxin A4 receptor; (ALX; synonym formyl
peptide receptor; FPR2) compared to MI-saline group. The levels of pro-resolving mediators
RvD1, RvD2, Maresin 1 (MaR1) and Lipoxin A4 (LXA4) were increased in spleens from RvD1
injected mice at d5 post-MI. RvD1 administration reduced macrophage density, ccr5 and cxcl5
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levels at d5 post-MI compared to saline injected mice (both, p<0.05). Increased transcripts of
mrc-1, arg-1 and Ym-1; (all, p<0.05) suggest macrophage-mediated clearance of necrotic cells in
RvD1-groups. RvD1 reduced the pro-fibrotic genes (colla1, coll2a1 and tnc (all; p<0.05) and
decreased collagen deposition, thereby reducing post-MI fibrosis and thus stabilizing the
extracellular matrix. In summary, RvD1 and Lipo-RvD1 promote the resolution of acute
inflammation initiated by MI, thereby delaying the onset of heart failure.

Graphical abstract
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1. Introduction
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Delayed or diminished resolution of inflammation is the key process that advances the
pathophysiology of many diseases, including congestive heart failure, atherosclerosis and
peripheral artery disease [1–3]. Persistent, unresolved inflammation is the major unifying
component in the progression of heart failure following myocardial infarction (MI). Post-MI
cytokine inhibitory anti-inflammatory treatments have been unsuccessful to treat defective
resolution of inflammation leading to congestive heart failure. With the failure of
cyclooxygenase (COX)-2 inhibitors, rofecoxib and celecoxib, [4, 5] and TNF-α inhibitor
trials [6] in clinical settings, novel directions to resolve inflammation are necessary. Post-MI
resolution of inflammation is an active, dynamic process following an acute inflammatory
response, demonstrated by the synchronic temporal and spatial activities of neutrophils and
macrophages. The overactive neutrophils are associated with major secretions of proinflammatory mediators and directly promote cardiomyocyte death [7]. In cardiac healing, it
is necessary to discontinue the overactive priming of neutrophils in order to resolve
inflammation. Thus, as a part of the post-MI resolution process, several specialized proresolving lipid mediators (SPM) are produced during the neutrophils-monocyte trafficking
and cell-cell interaction. The interactions of neutrophils, platelets and macrophages
promotes the generation of specialized pro-resolving lipids, including lipoxins, resolvins,
protectins, and maresins, with their functions being to limit neutrophil recruitment and
promote the resolution of acute inflammation [3].
Excessive intake of n-6 polyunsaturated fatty acids promotes non-resolving post-MI
inflammation, leading to early left ventricle (LV) dysfunction [2, 8]. However, the role of
novel pro-resolving lipid mediators, generated endogenously from omega-3 essential fatty
J Mol Cell Cardiol. Author manuscript; available in PMC 2016 July 01.
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acids, is unaddressed in post-MI remodeling. Our previous study suggests that
docosahexaenoic acid (DHA) is more potent than eicosapentaenoic acid (EPA) in
controlling chronic inflammation in lupus-prone mice [9]. Analysis of the DHA bioactive
metabolome revealed novel bioactive molecules, named as Resolvins (RvD1-RvD6), which
control neutrophil priming and re-program inflammatory macrophages towards the healing
response. Resolvins are formed by enzymatic conversion of DHA (D-series) and EPA (Eseries) [10]. Another pathway to form the D-series resolvins is triggered by aspirin, which
acetylates COX-2 that converts DHA into 17R-HDHA. 17R-HDHA is then converted by 5LOX to create AT-RvD1 [3]. The pro-resolving role of RvD1 has been studied [11] in a
number of systems including metabolic disease and infections [12, 13]. The rapid
conversion of RvD1 by eicosanoid oxidoreductase to 8-oxo- and 17-oxo-RvD1 dramatically
lowers its bioactivity [14]. In the present investigation, we determined the role of liposomal
RvD1 (Lipo-RvD1) and RvD1 in post-MI resolution of inflammation and LV remodeling.
RvD1 was formulated into multilamellar liposomes to increase the stability of RvD1.
Furthermore, we determined the impact of RvD1 on splenic remodeling post-MI. Our study
delineates that both Lipo-RvD1 and RvD1 activate the post-MI resolving phase by limiting
neutrophil-activation at the LV and spleen, furthermore clearing macrophages from the
injured LV to improve LV function. RvD1 discontinued the priming of neutrophils and
promoted the biosynthesis of pro-resolving bioactive lipid mediators, including RvD2,
MaR1, and LXA4, in the spleen. Thus, our results demonstrate the host protective actions of
RvD1, as well as a novel route of administration via incorporation into multilamellar
liposomes. In summary, RvD1 altered neutrophils kinetics at the splenic reservoir and LV,
leading to improved resolution of inflammation and attenuated cardiac remodeling post-MI.

2. Methods
Author Manuscript

2.1 Animal care and compliance
All animal surgery procedures and treatments were conducted according to the “Guide for
the Care and Use of Laboratory Animals” (8th Edition. 2011), and AVMA Guidelines for
the Euthanasia of Animals: (2013 Edition) and were approved by the Institutional Animal
Care and Use Committee at the University of Alabama at Birmingham, USA.
2.2 Materials
Egg phosphatidylcholine (EPC-35), DSPE-PEG (2000) (1,2-distearoyl-sn-glycero-3phosphoethanolamine (polyethylene glycol)-2000] were obtained from Avanti polar lipids
(Alabaster, AL, USA). Cholesterol and RvD1 were obtained from Sigma, (St. Louis, MO,
USA) and Cayman chemicals, (Ann Arbor, MI, USA) respectively.

Author Manuscript

2.3 Preparation and characterization of RvD1-liposomes
PEGylated liposomes containing RvD1 were prepared from a mixture of phospholipids by
utilizing the film extrusion method. [15] The liposomes were characterized for size and
polydispersity index using dynamic light scattering for colloidal size measurements.
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2.4 RvD1-liposomes size measurements
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The average hydrodynamic diameter and the polydispersity index of the liposome
dispersions were determined by dynamic light scattering using a Malvern zetasizer nano
(Malvern Instruments Ltd.; Worcestershire, United Kingdom) at 25°C using an argon-ion
laser (488 nm) operating at 10.4 mW (Uniphase). The polydispersity index was calculated
according to the method of Zhao et al [16]. The size of the PEGylated liposomes was found
to be in between 100 and 150 nm with a polydispersity index below 0.20, indicating a
relatively homogenous size distribution.
2.5 Zeta potential measurements

Author Manuscript

Electrophoretic mobility measurements (Zetasizer Nano-Z, Malvern instruments, UK) were
performed after dilution of the liposomes in HEPES buffer pH 7.5. The instruments were
calibrated using polystyrene latex beads of defined zeta potential. The mean zeta potential of
PEGylated liposomes was found to be −25 mV.
2.6 Coronary artery ligation surgery in mice and RvD1 treatment plan
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C57BL/6J mice of 8–12 weeks old were obtained from Jackson Laboratory (Bar Harbor,
Maine, USA) and were maintained under constant temperature (19.8–22.2°C). The mice
were given free access to water and standard chow diet. The mice were divided into 4
groups- (1) Group-1 as a control group with no surgery (day 0: no-MI control), (2) Group-2
as MI-saline group having MI surgery with vehicle treatment, (3) Group-3 administered
liposomal-RvD1, 3 hr post-MI (Lipo-RvD1), (4) Group-4 treated RvD1, 3 hr post-MI
(RvD1). To induce MI, mice were subjected to the surgical ligation of the left anterior
descending coronary artery, as described previously [17]. In brief, the mice were
anesthetized with 2% isoflurane and the left anterior descending coronary artery was
permanently ligated using nylon 8-0 sutures (ARO Surgical Instruments Corporation, CA,
USA) in a minimally invasive surgery. Prior to MI surgery, carprofen (5 mg/kg;
subcutaneous (SQ) and buprenorphine (0.1 mg/kg, SQ) were administered to reduce pain.
The mice were injected with either Lipo-RvD1 (3 µg/kg/day; SQ) or RvD1 (3 µg/kg/day;
SQ) 3 hours post-MI and monitored for day (d)1 or d5 necropsy samples.
2.7 Echocardiography

Author Manuscript

For the echocardiography analysis, mice were anesthetized using 1.5–2.0% isoflurane in a
100% oxygen mix. Electrocardiograms and heart rates were monitored using a surface
electrocardiogram. Images were acquired using the Vevo 770 in vivo imaging system
(Visual Sonics, Canada) equipped with probes up to 40 MHz and a resolution of 30 µm.
Short and long axis images were acquired at heart rates >400 beats/min to achieve
physiologically relevant measurements. Measurements were taken from the two dimensional
parasternal long-axis (B-mode) and short-axis (M-mode) recordings from the mid-papillary
region. Echocardiographic studies were performed before necropsy for d0 control mice and
for d1 and d5 post-MI mice. For each variable, three images from consecutive cardiac cycles
were measured and averaged by operator blinded to genotype [17].
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2.8 Necropsy and infarct area analysis
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No-MI control day (d0), d1 or d5 post-MI RvD1 treated, and saline injected mice were
anesthetized under 2% isoflurane anesthesia in 100% oxygen mix. To collect plasma,
heparin (4 IU/g; I.P.) injection was used. The blood was collected from the carotid artery
after 5 minutes post heparin administration, and centrifuged for 5 min to isolate plasma. The
lungs and left and right ventricles were collected, weighed and processed as previously
described [8]. The spleen was dissected by making incision in left of the peritoneal wall. The
spleen was weighed and photographed using canon DSLR camera. The spleen was divided
into two halves and the broad and concave portion was fixed in 10% zinc formalin for IHC
and the rest of the spleen was snap-frozen for biochemical and molecular analysis.
2.9 LV and spleen histology and immunohistochemistry

Author Manuscript

For histological measurements, LV transverse and spleen sections were embedded in
paraffin and sectioned. For assessment of neutrophils and macrophages, paraffin-embedded
sections were deparaffinized in citrisolv and rehydrated through graded ethanol. Heatmediated antigen retrieval was performed to expose antigen epitopes (Target Retrieval
Solution, Dako S1699) using a pressure cooker (BioSB Tinto Retriever). Sections, blocked
with normal rabbit or goat serum as per antibody, were incubated with rat anti-mouse
neutrophils (CL 8993AP, clone 7 1:50; Cedarlane) and rat anti-Mac-3 monoclonal antibody
(CL 8943AP, clone M3/84; 1:100 dilution; Cedarlane). Neutrophils and macrophages
staining were followed with the Vectastain Elite ABC kit (Vector). The slides were mounted
using permount and allowed to dry for use in image analysis [17].
2.10 Metabololipidomics using liquid chromatography-tandem mass spectrometry (LCMS/MS)
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Briefly, spleens were suspended in 1.0 ml cold methanol and gently homogenized,
afterwards they were kept on ice for 1h to allow for protein precipitation. Lipid mediators
(LM) were profiled as described in Colas et al [18]. LM were extracted using SPE on C18
columns and methyl formate fractions were taken for LC-MS/MS-based lipidomics. The
spleen samples from no-MI control, MI-saline and RvD1-treated group were analyzed on a
LC -MS/MS system, QTRAP 6500 (ABSciex). Calibration curves were obtained using
synthetic and authentic LM mixtures. Linear calibration curves for each were obtained with
r2 values in the range 0.98–0.99. Quantification was carried out based on peak area of the
MRM transition and the linear calibration curve for each compound and biosynthetic
pathway marker as in Colas et al [18].
2.11 Picrosirius red staining

Author Manuscript

For PSR staining, paraffin-embedded unstained sections of LV tissue were deparaffinized in
citrisolv (Fisher Scientific, USA) and rehydrated through subsequent washes of ethanol.
After a wash with water, phosphomolybdic acid (0.2% in water) was placed on the section.
A subsequent wash with water was followed by addition of sirius red, 0.1 % in saturated
picric acid (26357-02) and then application of 0.01N hydrochloric acid. Then, slides were
dehydrated and mounted using permount. The slides were allowed to dry for image
acquisition and analysis. [19].
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2.12 Image analysis for IHC and PSR staining
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For each slide per mouse, a total of 4–6 images were acquired from spleen and LV infarct
area including border zone using a microscope (BX43) with an attached camera (Olympus
DP73). The images were captured using the cellSens Dimension program (Olympus version
1.9) and then analyzed for percent area stained using Image-Pro Premier 64-bit analyzer
software (Image Pro Premier, Cybernatics). The percent stained area was determined by the
image analysis software and averaged to determine the percent area stained for neutrophils
(spleen and LV), macrophages and collagen (PSR) density in the infarcted area.
2.13 RT2profiler inflammatory and extracellular matrix (ECM) PCR array

Author Manuscript

Gene expression profiling was done using inflammatory and ECM PCR arrays in frozen
infarcted (LVI) samples for no-MI control, MI saline, Lipo-RvD1 and RvD1-injected mice
as previously described [8]. Briefly, RNA was isolated and cDNA synthesis was performed.
The samples were loaded on RT2-PCR plate (Inflammatory Cytokine and Receptor by
Qiagen PAMM-011E and Mouse ECM & adhesion molecules PAMM-013E) and ran on an
ABI 7900HT. Gene levels were normalized to hypoxanthine phosphoribosyltransferase
(Hprt-1) as the housekeeping gene. The results were reported as 2−ΔCt (ΔΔCt) values.
2.14 Quantitative real-time PCR for measurements of gene transcripts

Author Manuscript

For qPCR, reverse transcription was performed with 2.0 µg of total RNA using
SuperScript® VILO cDNA Synthesis kit (Invitrogen, CA, USA). Quantitative PCR for ALX/
FPR2, ptgs-1, ptgs-2, hmox-1, Alox-12, Alox-5, tnf-α, IL-6, ccl2, IL-1β, CD163, arg-1,
mrc-1 and Ym-1 genes was performed using taqman probes (Applied Biosystems, CA, USA)
on master cycler ABI, 7900HT. Gene levels were normalized to Hprt-1 as the housekeeping
control gene. The results were reported as 2−ΔCt (ΔΔCt) values. All the experiments were
performed in duplicates with n=3–4/group.
2.15 LV protein extraction for immunoblotting
The LVI tissues were processed for protein extraction as previously described [8].
2.16 LV protein immunoblotting
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Electrophoresis of 10 µg of LVI protein were performed using criterion XT bis-tris 4–12 %
gel (Bio-Rad Inc.) in MOPs Buffer (Bio-Rad) and transferred on nitrocellulose membrane
(BioRad Inc.). The total protein stain was acquired using pierce reversible protein stain,
nitrocellulose membranes kit (Thermo Scientific Inc.). The membrane was blocked for 1 hr
at room temperature, using 5% non-fat milk powder (Bio-Rad) dissolved in TPBS and
probed with primary antibody [COX-2 1:1000, COX-1 1:1000, 5-LOX 1:200 (abcam) and
ALX/FPR2 1:500 (Santa cruz)] overnight at 4°C followed by secondary antibody (Biorad).
The proteins were detected using the femto chemiluminescence detection system (Pierce
Chemical, Rockford, IL, USA). Densitometry was performed using Image J software (NIH,
USA).

J Mol Cell Cardiol. Author manuscript; available in PMC 2016 July 01.

Kain et al.

Page 7

2.17 Venn diagram, hierarchical clustering of inflammatory and ECM array
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Venn diagram, hierarchical cluster, and heat maps were generated for RT2 profiler
inflammatory and ECM PCR array data using cluster 3.0 and java tree view software. The
values of genes were normalized by taking geometric mean of the genes for statistical
significance. For Venn diagrams the values were normalized to no-MI d0 control at the
respective time points and evaluated for statistical significance.
2.18 Statistical analysis

Author Manuscript

Data are expressed as mean and SEM. Statistical analyses were performed using Graphpad
prism 5. Analysis of variance (ANOVA) followed by Newman–Keuls post-hoc test was
used for multiple comparisons of post-MI d1, d5 groups (RvD1 and saline injected
compared to no-MI control. All immunoblotting densitometry data was normalized to total
protein/lane. For 2 groups comparison, the student-t test (unpaired) was applied, p<0.05 was
considered as statistically significant.

3. Results
3.1 RvD1 reduced LV hypertrophy and preserved transient depletion of splenic reservoir
post-MI

Author Manuscript

To determine the post-MI gravimetric changes after RvD1 treatment, LV, spleen and lung
masses were measured. Both Lipo-RvD1 and RvD1-injected groups reduced the LV mass to
body weight ratio compared to the MI-saline group at d5-post-MI, indicating a reduced postMI LV remodeling response (Table 1A). Post-MI spleen mass was decreased within 24 hr
(post-MI d1) in MI-saline group, suggesting a depletion feature of the splenic reservoir in
post-MI remodeling. We observed a significant decrease in spleen mass at d1 and increase at
d5 post-MI in MI-saline compared to no-MI control group. Interestingly, Lipo-RvD1 and
RvD1 treated mice did not display significant differences in spleen mass at d1 compared to
no-MI control and decrease by d5 post-MI compared to saline-injected MI mice (Table 1A).
Thus, gravimetric analyses indicated that RvD1 administration decreased LV hypertrophy
and reduced transient changes in the splenic reservoir post-MI.
3.2 RvD1 improved LV function and pulmonary edema post-MI

Author Manuscript

To assess the actions of RvD1 on LV function post-MI, echocardiography measurements
were performed. Echocardiography data reflected a reduced fractional shortening at d1 and
d5 in MI-saline group compared with no-MI control, indicating post-MI LV dysfunction.
Both Lipo-RvD1 and RvD1 injected groups improved their fractional shortening compared
to MI- saline group (Table 1B). Both Lipo-RvD1 and RvD1 groups showed lower dilation in
LV geometry as evidenced by their decreased end systolic dimension (ESD) and end
diastolic dimension (EDD) at d5 post-MI. Lipo-RvD1 and RvD1 treated mice showed a
significant decrease in lung mass to body weight ratios compared to MI-saline injected mice
at d5 post-MI (Table 1A). The echocardiography and gravimetric measurement outcomes
suggested that RvD1 reduced both LV dysfunction and pulmonary edema post-MI.
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3.3 RvD1 reduced neutrophil recruitment in LV
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To investigate the impact of RvD1 on neutrophil infiltration post-MI, neutrophils density
was measured. In response to MI-mediated acute inflammation, neutrophil infiltration is an
immediate onset event during wound healing to resolve inflammation [20]. Post-MI, there
was a robust neutrophil priming effect in all the groups which peaked at d1 in MI-saline
group. Lipo-RvD1 and RvD1 injected groups showed unaltered and immediate neutrophil
priming infiltration at d1 compared to MI-saline group. However, RvD1 group exhibited
higher neutrophils infiltration at d1 post-MI when compared with Lipo-RvD1 and MI-saline
groups. Presumably, this may be due to the immediate unavailability of RvD1 from
liposomal formulation and owing to RvD1 encapsulation in Lipo-RvD1 compared to RvD1
at d1 post-MI. As expected, no-MI naïve control did not show neutrophil infiltration in LV
(Figure 1A and C). The chemical structure of RvD1 is provided in Figure 1B. Of note,
neutrophils priming was reduced to the infarct area in the Lipo-RvD1 and RvD1 injected
group, while neutrophils recruitment continued in the MI-saline group at d5 post-MI. This
was complemented by decreased expression of ccr5, ccl7 and cxcl5 gene expression in the
infarcted area (Supplementary table 1). RvD1 is known to interact with ALX/FPR2 [21, 22]
therefore ALX/FPR2 mRNA and protein expression was measured. At d1 to d5 post-MI,
there was a delay to increase ALX/FPR2 expression in MI-saline group, accompanied with
higher neutrophil density. Both Lipo-and RvD1 treated groups showed a more rapid increase
in ALX/FPR2expression from d1 to d5 post-MI compared with MI-saline group; supporting
the discontinuation of neutrophil priming for these groups (Figure 1D and supplementary
Figure 2) as a result of the pro-resolving action of RvD1. Thus, reduced density of
neutrophils at d5 clearly indicated that RvD1 administration post-MI reduced neutrophil
recruitment and attenuated inflammation, leading to the early initiation of resolution.

Author Manuscript

3.4 RvD1 reduced neutrophils density in spleen that coordinated with LV
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Splenic metabolic activation is well documented in the pathogenesis of cardiac remodeling
and subsequent chronic heart failure [23–25]. Neutrophils are known to be present around B
lymphocytes in the spleen without inflammation [26] and their number increases in response
to inflammation. Thus, we evaluated the density of splenic neutrophils post-MI. We
observed a continuous increase in neutrophil population in the spleen at d1 post-MI (2.4%
±0.6%) to d5 post-MI (4.1%±0.1%) in MI-saline group compared to no-MI control.
However, consistent with the neutrophil density in LV, both Lipo-RvD1 and RvD1 injected
mice showed a robust increase in neutrophils, 3.4±0.5% and 4.1±0.4% respectively,
compared to the MI-saline group at d1 post-MI. By d5, both Lipo-RvD1 and RvD1 group
showed rapid clearance of neutrophils, 2.1±0.3% and 2.4±0.2% respectively, compared to
MI-saline group (Figure 2A and B). We next investigated whether ALX/FPR2 may be
involved in mediating the actions of RvD1 in these spleens, perhaps in a similar manner as
that observed in the LV infarcted area. RvD1 stimulated relatively higher expression of
ALX/FPR2 in the spleen compared with infarcted area at d5 post-MI (Figure 2C). The data
indicated that RvD1 expanded neutrophils activation at d1 post-MI for priming the immune
cells. However, at d5 post-MI, RvD1 reduced neutrophil recruitment by activating ALX/
FPR2 to pave the way for other immune cells and to expedite effective resolution thereby,
limiting ventricular remodeling.
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3.5 RvD1 promoted the production of SPM in spleen to resolve post-MI inflammation
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Our results showed that RvD1 acted on the spleen and LV to resolve post-MI inflammation.
We then questioned whether RvD1 regulated lipid mediators in the spleen post-MI. Using
LC-MS/MS-based lipid mediator metabololipidomics, we identified SPMs in the spleen at
d5 post-MI in both MI-saline and RvD1 treated mice and compared their levels to no-MI
control mice. In accordance to previous findings [27] with spleens from no-MI mice, we
identified mediators from all three major bioactive lipid mediator metabolomes (Figure 3
and Supplementary Table 2), which includes the DHA derived D-series resolvins, protectins
and maresins, the EPA derived E-series resolvins and the arachidonic acid derived lipoxins.
These were all identified in accordance with published criteria that include matching
retention times and MS-MS fragmentation (Figure 3A and B) [18]. The lipid mediator
profiles of spleens from mice at d5 post-MI showed elevated levels of a number of proinflammatory mediators, including the arachidonic acid derived leukotriene B4 and
prostaglandin D2. Spleens from RvD1 treated mice at d5 post-MI showed increase in a
number of pro-resolving mediators, including RvD2, 17R–RvD1, MaR1, LXA4 and LXB4
(Supplementary Table 2). These results suggested that administration of RvD1 post-MI
promotes the formation of SPM in the spleen that may contribute to organ protection and
improved resolution of inflammation.
3.6 RvD1 promoted macrophages clearance by d5 post-MI

Author Manuscript

Macrophages are versatile, heterogeneous, big eaters whose role is to engulf necrotic
cardiomyocytes and apoptotic neutrophils. Macrophages clear tissue debris and initiate ECM
deposition in the infarcted area post-MI [20]. To understand the impact of RvD1 on
macrophage kinetics post-MI, we further assessed the macrophage density and phenotypes
post-MI. LV IHC results showed that RvD1 injected mice decreased macrophage density
(mac-3) compared to MI-saline group at d5 post MI (Figure 4A–B). The decreased
expression of chemokine receptors ccl4 (mip-1β), ccr2 and cx3cr1 (all p<0.05) indicated the
rapid clearance of macrophages with a simultaneous decrease in the macrophage-derived
chemokine (MDC/ccl22, p<0.05) (Figure 4; Supplementary table 1) in RvD1-injected
groups. Thus, RvD1 stimulated macrophages emigration and thus prevented accumulation in
the infarcted area at d5 post-MI by regulating both monocyte trafficking and their clearance
from LV infarct area.
3.7 RvD1 contained inflammation and promoted inflammation resolution post-MI
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To evaluate the impact of RvD1 on acute inflammatory response superimposed on the
resolving response in post-MI settings, we measured 84 inflammation-associated genes.
Array data showed that 20 genes were upregulated and 11 genes downregulated for the MIsaline group in MI settings. However, the Lipo-RvD1 treated group showed 8 upregulated
and 18 down-regulated genes, while in the RvD1 group only 1 gene was upregulated while
16 were down-regulated. Interestingly, at d5 post-MI both Lipo-RvD1 and RvD1 injected
mice exhibited down regulation of pro-inflammatory genes (Figure 4C–D). The decreased
cxcl5 and ccl2 (both p<0.05) expression in both RvD1 groups confirmed the reduction of
neutrophils and early clearance of macrophages at d5 post-MI. The Venn diagram (Figure
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4C–D) reflects the down regulation of pro-inflammatory genes in RvD1-injected groups
compared to MI-saline, which delineated the faster resolution of inflammation.
3.8 RvD1 promoted alternative macrophage polarization at d5 post-MI

Author Manuscript

Macrophages are heterotypic populations in the post-MI setting depending upon milieu,
whether to promote or limit LV remodeling [23]. We explored the action of RvD1 on
macrophage polarization at d5 post-MI. Tnf-α, IL-1β, ccl2 and IL-6 were classified as
classical macrophage markers (M1; Figure 5A) while mrc-1, arg-1 and Ym-1 were classified
as alternative macrophage (M2; Figure 5B). Results from M1 and M2 gene expression
measurements revealed that RvD1 played a dual role in macrophage activation and
polarization at specific time points. RvD1 rapidly increased the initial neutrophil infiltration,
displayed by an increase in expression of tnf-α and ccl2 at d1 post-MI while at d5 post-MI it
reduced neutrophil recruitment and expedited the clearance of neutrophils by macrophages
(Figure 5A). This was supported by the increase in expression of resolving M2 macrophages
markers mrc-1, arg-1 and Ym-1 (Figure 5B) in Lipo-RVD1 and RvD1-treated groups,
suggesting the clearance of apoptotic neutrophils, fibroblast debris and dead myocytes.
Since spleens of RvD1-treated groups generated SPMs at d5 post-MI, we asked the question
of whether there is a change in macrophages polarization in the spleen as well. Gene
expression data suggests that both Lipo-and RvD1 treated groups increased the expression
of tnf-α at d1, which decreased at d5 post-MI with a simultaneous increase in the expression
of arg-1 and mrc-1 (Supplementary Figure 3). These results indicated that RvD1 initiated
resolution by expediting M2 gene expression and SPMs without altering the acute
proinflammatory phase post-MI.

Author Manuscript

3.9 RvD1 stimulated 5-LOX and ALX/FPR2 leading to attenuated cardiac remodeling postMI
5-LOX has a supporting role in wound healing post-MI [28]. Since, 5-LOX is one of the
enzyme involved in RvD1 biosynthesis, we measured the action of RvD1 on 5-LOX. As
expected, 5-LOX was upregulated in the MI-saline group from d1 to d5 post-MI. Both
RvD1-injected groups showed higher expressions of 5-LOX at the mRNA and protein levels
compared to MI-saline group post-MI (Figure 6A–B) along with increases in ALX/FPR2
protein expression (Figure 6C–D). These results suggest that RvD1 mediated resolution by
stimulating 5-LOX and ALX/FPR2 in order to facilitate the resolution of inflammation as
part of the post-MI repair mechanism.
3.10 RvD1 reduced COX-1 and COX-2 expression in resolving phase

Author Manuscript

COX-1 and COX-2 resolves inflammation post-MI by generating pro-inflammatory and proresolving mediators in order to clear the post-MI debris of dead cells [29]. RvD1 did not
alter COX-1 and −2 levels at d1 post-MI, however, it did decrease the expression of both
COX-1 and −2 at d5 post-MI (Figure 6E–H). Thus, the limited expression of COX-1 and-2
in both Lipo-RvD1 and RvD1 treated groups indicated reduced inflammation at d5 post-MI
without alteration of the acute inflammatory phase.
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3.11 RvD1 reduced collagen deposition post-MI

Author Manuscript

Collagen deposition is a subsequent event occurring after the acute inflammatory response
which leads to myocardium stiffness and ultimately LV dysfunction post-MI. In order to
evaluate whether RvD1 could limit myocardial ECM deposition post-MI, we measured PSR
stained area in the infarct zone at d0, d1 and d5 post-MI in MI-saline and RvD1-treated
groups. At d5, MI-saline group showed 23±4% increase in collagen levels compared to d1
or d0 controls. However, both Lipo- and RvD1 treated groups reduced collagen deposition
to 13±1% and 14±1% respectively at d5 post-MI (Figure 7A–B). Thus, RvD1 treatment
initiated the early reparative phase to limit collagen deposition and improve the LV healing
process.
3.12 RvD1 reduced ECM gene transcripts post-MI

Author Manuscript

To identify the manner in which RvD1 influences the ECM remodeling post-MI, we
evaluated the RvD1 action on ECM remodeling. We used a gene array for 84 ECM and
adhesion molecules in post-MI settings in the LV infarct area (Figure 7C–D). At d1 post-MI,
9 genes in Lipo-RvD1 and 1 gene in RvD1 group was upregulated compared to the MIsaline group where 21 genes were upregulated. Similarly, Lipo-RvD1 and RvD1 showed an
increase in 6 genes and 1 gene respectively at d5 post-MI. The decreased expression of fn-1,
Icam, CD44, coll1a1, tnc and mmp-9 (Supplementary table 3) and the increase in Timp-1
(all, p<0.05) at d5 post-MI in RvD1-injetced groups indicated a reduced ECM deposition in
the LV. Thus, RvD1 activated early resolution of inflammation and modulated ECM
regulatory genes to reduce post-MI fibrosis, thereby improved LV function.

4. Discussion
Author Manuscript

The post-MI resolution of inflammation is an active, dynamic process that dampens proinflammatory signals without altering the host defense, however, uncontrolled inflammation
often leads to congestive heart failure [1–3]. Thus, in the present investigation, we have
assessed the role of RvD1 and Lipo-RvD1 formulation in the post-MI setting. RvD1
treatment; 1) prevented early changes in the splenic reservoir and improved LV function; 2)
reduced neutrophil density in the spleen and discontinued neutrophil recruitment in LV; 3)
increased pro-resolving lipid mediators level in the spleen and stimulated macrophages
clearance to promote early resolution in the LV; 4) initiated 5-LOX and the ALX/FPR2 as
well as modulated COX-1 and COX-2 expression and 5) reduced ECM gene expression and
collagen deposition, thereby limiting the progression towards LV dysfunction. Thus, the
present study suggests that the DHA-derived bioactive lipid mediator, RvD1, exerts potent
pro-resolving actions in MI-mediated injury.

Author Manuscript

Lipid mediators, like RvD1, are subject to rapid inactivation in vivo [30]. The stability of
RvD1 and its delivery are the key challenges in formulation and use as therapeutic tool for
long-term treatment. Owing to these local inactivation pathways, a delivery approach that
reduces local metabolism, increasing the half-life and potency of this potent pro-resolving
mediator, would be desirable. Herein, we encapsulated RvD1 in a liposomal formulation to
offer stability and future translational use in the chronic inflammatory heart failure setting
which demands a long term treatment. RvD1 is endogenously produced as a consequence of
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injury or infection at the intended site of action to act as an autacoid [3]. In this study we
demonstrated that liposome incorporated RvD1 retained its potent pro-resolving actions,
suggesting this methodology may also be employed in the delivery of other SPMs, including
E-series resolvins, lipoxins, protectins or maresins.

Author Manuscript

The first action of RvD1 is a preserved splenic depletion, revealed by attenuated transient
post-MI mass loss. Recent studies suggest that post-MI spleen metabolic activity and splenic
monocytes are contributors in the development of chronic heart failure [31, 32]. In the
current post-MI study, the RvD1 mechanism of action resolves the inflammation by
remitting neutrophil infiltration in both the spleen and LV by conserving transient changes
in splenic weight. We observed a major decrease in spleen weight at d1 post-MI, suggesting
a quick depletion of immune cells from the splenic reservoir. Interestingly, mice treated with
RvD1 retained their splenic mass consistently from post-MI d1 to d5, suggesting RvD1
serves to retain the splenic reservoir. This accounts for the notion that the spleen serves as a
constant reservoir of immune cells. Presented immune cell kinetics align with the findings
by Leuschner et al, that the spleen acts as an immediate reservoir of monocyte/ macrophages
which patrol in the early phase of myocardium injury [33].

Author Manuscript
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The second action of RvD1 is evidenced by the reduced neutrophils density, increased proresolving mediators and relatively higher expression of ALX/FPR2 in the spleen rather than
the LV. In the spleen, neutrophils are located around B lymphocytes in order to help their
activation and to offer a first rapid response to MI injury or infection-mediated
inflammation. Puga et al have shown that neutrophils in the spleen inherit the ability to
interact with B cells or B lymphocytes in order to produce antibodies, which blood
lymphocytes cannot do [26]. Thus, splenic neutrophils immediately get activated in response
to post-MI inflammation and their cell-cell interaction activates other cell types to resolve
inflammation. RvD1 regulates B cell activation, thereby stimulating a rapid defense
mechanism [34]. This correlates with the simultaneous rush of neutrophils at d1 post-MI in
RvD1 group, both in the LV and spleens, indicating mononuclear cells coordinate between
the LV and spleen, so as to expedite the resolution of inflammation. Reduced neutrophils
priming was further supported by the activation of ALX/FPR2 in RvD1 injected mice. The
activation of ALX/FPR2 at d5 post-MI is complemented with previous findings where
neutrophils were decreased [35, 36], suggesting an increase in mononuclear cells
phagocytosis. RvD1 stimulated the ALX/FPR2 not only at the site of wound healing, i.e LV,
but it also had a robust action in the spleen, suggesting a dynamic role of the spleen in
resolving post-MI inflammation by limiting pro-inflammation. Thus, an unaltered neutrophil
response at d1 post-MI by RvD1 plays a pivotal role in resolving inflammation. This could
be an effective pharmacological approach, as RvD1 increases the levels of bioactive lipid
mediators in the spleen to expedite the resolution of inflammation. Here, we report for the
first time that these SPMs are elevated in the spleen post-MI and are even further elevated
by RvD1 administration, suggesting the spleen as one of the major organ that coordinates
with the LV post-MI injury. Thus, post-MI administration of RvD1 shortens the span of the
pro-inflammatory window due to an increase of pro-resolving lipid mediators in the spleen.
Mass spectrometry results showed increased levels of RvD1, RvD2, MaR1 and LXA4; this
indicates that RvD1 has multiple actions through increasing levels of different SPMs in
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order to activate the resolution phase. Our findings are in parallel with the enhanced diabetic
wound healing capacity of RvD1 in diabetic (db/db) mice. This provides evidence on the
utilization of bioactive lipid molecules for the effective resolution of inflammation in several
cardiovascular complications and other unresolved inflammation-mediated disease [35].

Author Manuscript

The third main action of RvD1 identified in the present study is that it shortens the acute
pro-inflammatory window. RvD1 did not alter the acute inflammatory response, marked by
an increase in LV expression of cxcl9, ccl1, ccr10 and few M1 markers at d1 post-MI.
Further, the RvD1 action decreased LV expression of chemokine receptors ccr2, ccr5, cxcr2
and cxcr5 at d5, indicating SPMs promote resolution by shortening the stay of neutrophils at
the site of injury post-MI [37]. Administration of RvD1 reduced neutrophil recruitment at d5
post-MI in the spleen and LV, coinciding with the down regulation of pro-inflammatory
cytokines tnf-α, IL-1β, ccl2 and IL-6 in the resolving phase without altering the acute
inflammatory response at d1. Of note, at d1 tnf-a levels were increased in RvD1 injected
mice, indicating an unaltered host-defense in response to MI. Both IL-1β and tnf-α prolongs
the neutrophil life-span, which prolongs the proinflammatory environment to extend
granulocyte survival. Further, at d5-MI granulocytes undergo apoptosis, a process which is
capable of attenuating inflammation, indicating the resolving phase of inflammation [38].
Post-MI wound healing coordinates to increase spleen and LV neutrophils with IL-1β and
tnf-α via RvD1 at d1 post-MI. Additional, down regulation of IL-1-β and tnf-α at d5 post-MI
suggested that RvD1 shortens the prolonged inflammatory phase by decreasing the
transmigration of neutrophils to the site of injury.
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The fourth main action of RvD1 post-MI is the clearance of macrophages and expression of
the resolving macrophage phenotype. The directed migration of neutrophils is referred to as
chemotaxis, a process which regulates intracellular signaling, allowing neutrophils to detect
a gradient of attractant, polarize and migrate rapidly towards the chemoattractant in order to
resolve post-MI inflammation [39]. RvD1 promoted CD44 , which is important for the
containment of chronic inflammation and enrichment of fibroblasts post-MI [40]. CD44 is
associated with enhanced, prolonged neutrophil and macrophage infiltration and also an
increase in expression of proinflammatory cytokines in the infarcted myocardium [40].
Activation of CD44 expression in MI-saline group was associated with overactive
neutrophils at d5 post-MI. RvD1 administration post-MI gave rapid exodus of the
macrophages from the LV along with a decreased cxcl5 and ccl2 expression. These results
highlight the importance of limiting neutrophil infiltration in the local chemotaxis altered
macrophage population and macrophage plasticity. Increased macrophage phagocytosis in
RvD1 treated mice initiated apoptosis of neutrophils which expedites the resolution of
inflammation. This was further supported by enhanced expression of resolving macrophage
markers mrc-1, arg-1 and Ym-1, thereby improving resolution of inflammation.
The fifth action of RvD1 is a consequence of activated inflammation-resolution axis leading
to subsequent dynamic alterations in the ECM. ECM deposition is the progression following
the inflammatory response post-MI, coordinated by the up-regulation of ECM transcripts.
Resolution of inflammation overlaps with reorganization of ECM deposition following the
healing response post-MI. The poor regenerative capacity of the myocardium leads to the
formation of an irreversible scar, ultimately leading to the adverse remodeling of the
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myocardium [41]. RvD1 administration in mice not only resolves the inflammatory
response, but also reduced the expression of fibrotic genes, such as colla1, coll2a1 and tnc.
These observations suggest that RvD1 stabilizes the ECM by resolving inflammation. LOX
and COX are the key enzymes for generating potent lipid mediators, which primarily
coordinates the resolution of inflammation in pathophysiological settings [42]. Fredman et
al. reported that RvD1 favors synthesis of the pro-resolving lipid mediator, LXA4, via
limiting nuclear translocation of 5-LOX in inflammation [43]. RvD1 critically balanced
LOX enzymes by stimulating 5-LOX expression, which is essential for wound healing postMI [28]. Chronic, dissipating, and unresolved inflammatory response leads to ventricular
dysfunction post-MI. Thus, RvD1 has the potential to delay heart failure but still requires
long-term studies in order to prove its utilization in chronic heart failure management.
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In conclusion, we demonstrated that RvD1 mediates the pro-resolving actions, remitting
ungoverned inflammation associated with post-MI. RvD1 limited neutrophil recruitment in
the spleen and LV, increased resolving lipid mediators and altered the macrophages
phenotype post-MI. RvD1 promotes the resolution of inflammation and stabilizes the ECM
through regulating LOX and COX enzymes. Together, these results indicated that RvD1 has
a high potential to modulate the resolution pathophysiology in order to limit cardiac
remodeling and thereby delay the progression of heart failure following MI.
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Highlights
We provide evidence on Resolvin D1 (RvD1) action in healing heart following
myocardial infarction (MI) where;
1)

RvD1 acted on ALX/FPR2 receptor and discontinued neutrophil priming in
spleen and LV post-MI.

2)

RvD1 stimulated macrophages clearance from infarcted area to promote early
resolution of inflammation post-MI.

3)

RvD1 reduced ECM gene expression and collagen deposition thereby limited
left ventricle dysfunction post-MI.
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Figure 1. RvD1 reduced LV neutrophil density and activated ALX/FPR2 expression at d5 postMI

(A) Representative neutrophil IHC images of LV transverse section for MI-saline, LipoRvD1 and RvD1 injected group at d1 and d5 post-MI (Magnification 40X, 4–6 images/slide
were quantified/mouse, 3–5 mice/group, LV middle section at 1.25x, scale bar =50 µm). The
arrow indicate the neutrophils at d5 post-MI in MI-saline, Lipo-RvD1 and RvD1 injected
group (B) Chemical structure of RvD1, (C) Quantification of percentage stained area of
neutrophils in the LV IHC at d1 and d5 post-MI in MI-saline, Lipo-RvD1 and RvD1
injected groups, the absence of quantifiable neutrophils in the LV are presented as
“undetermined”. (D) mRNA expression of ALX/FPR2 in infarcted area of MI-saline, LipoRvD1 and RvD1 injected groups. *p<0.05 vs d0 no-MI control, $p<0.05 vs MI-saline at
respective day, n=3–5 mice/group/day.
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Figure 2. RvD1 reduced spleen neutrophils density and activated FPR2/ALX expression at d5
post-MI

(A) H& E images of the spleen of d0 controls and at d1 and d5 post-MI in MI-saline, LipoRvD1 and RvD1 injected group; scale bar= 50 µm, magnification=40X, 4–6 images/slide
were quantified/mouse, 3–5 mice/group. (B) Quantification of the percentage stained area of
neutrophils in the spleen IHC at d1 and d5 post-MI in MI-saline, Lipo-RvD1 and RvD1
injected groups. (C) mRNA expression of ALX/FPR2 in spleen in MI-saline, Lipo-RvD1
and RvD1 treated groups in control and at d1 and d5 post-MI. *p<0.05 vs d0 no-MI control,
$p<0.05 vs MI-saline at respective day; n=3-5/group/day.
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Figure 3. Mass spectrometry profiling of SPM (specialized pro-resolving lipid mediators) from
DHA, EPA and arachidonic acid bioactive metabolomes in spleen at d5 post-MI

(A) Representative Multiple Reaction Monitoring (MRM) traces for the identified lipid
mediators accompanying MS/MS spectra used for identification of LXA4 and MaR1. (B)
Accompanying MS/MS spectra used for identification of LXA4 and MaR1.
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Figure 4. RvD1 reduced macrophage density at d5 post-MI

(A) Representative Mac-3 IHC images of LV transverse section at d1 and d5 post-MI in MIsaline, Lipo-RvD1 and RvD1 respectively. (Magnification 40X, 4–6 images/slide were
quantified/mouse, 3–5 mice/group, LV middle section at 1.25x, scale =50 µm), *p<0.05 vs
MI-saline at d5 post-MI for Lipo-RvD1 and RvD1 treated groups (n=3–4 mice/group/day);
(B) Macrophages (mac-3) stained area in the LV IHC at d5 post-MI in MI-saline, LipoRvD1 and RvD1 treated groups. (C) Venn diagram representing post-MI inflammatory gene
expression in LVI regions of MI-saline, Lipo-RvD1 and RvD1 mice at d1 post-MI. (D)
Venn diagram representing post-MI inflammatory gene expression in infarcted area of MIsaline, Lipo-RvD1 and RvD1 mice at d1 and d5 post-MI. Red indicates ted genes expression
and green indicates led genes. Black indicates no change in genes. All the genes are
normalized to no-MI control.
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Figure 5. RvD1 promoted alternative macrophages polarization without altering proinflammatory response

Author Manuscript

Gene expression of (A) Classical M1 markers, (B) Alternative M2 markers in MI-saline,
Lipo-RvD1 and RvD1 treated groups. *p<0.05 vs d0 control, $p<0.05 vs MI-saline at
respective day; n=4 mice/group/day, Lowest gene expression values of IL-6, Arg-1 and
Ym-1 at d0 control are presented as “undetermined”.
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Figure 6. RvD1 activated 5-LOX, ALX/FPR2 and modulated COX-1 and COX-2

(A) Immunoblot representing 5-LOX expression (B) Densitometric analysis and mRNA
expression of 5-LOX (C) Immunoblot representing ALX/FPR2 expression (D)
Densitometric analysis and mRNA expression of ALX/FPR2 (E) Immunoblot representing
COX-1 expression (F) Densitometric analysis and mRNA expression of COX-1 (G)
Immunoblot representing COX-2 expression. (H) Densitometric analysis and mRNA
expression of COX-2. The protein and mRNA expression is measured in LV infarct of MIsaline, Lipo-RvD1 and RvD1 injected mice at d1 and d5 post-MI. *p<0.05 vs d0 no-MI
control, $p<0.05 vs MI-saline at respective day; n=3-4/group/day.
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Figure 7. RvD1 reduced post-MI LV collagen content and extracellular matrix transcripts

(A) Representative images of PSR staining in LV infarct of MI-saline, Lipo-RvD1 and
RvD1 injected mice at d1 and d5 post-MI (Magnification 40X, 4–6 images/slide were
quantified/mouse, 3–5 mice/group, LV middle section at 1.25x, scale =50 µm). (B) Collagen
percentage stained area in the LV at d5 post-MI in MI-saline, Lipo-RvD1 and RvD1 injected
groups. *p<0.05 vs d5 MI-saline; n=3-4/group/day (C) Venn diagram representing post-MI
ECM remodeling genes in LV infarct of MI-saline, Lipo-RvD1 and RvD1 injected mice at
d1 post-MI. (D) Venn diagram representing post-MI ECM remodeling genes in LV infarct
of MI-Saline, Lipo-RvD1 and RvD1 injected mice at d5 post-MI. Post-MI gene expression
are normalized to respective d0 control. Red indicates ↑ed and green indicates ↓ed gene
expression. Black indicates no change in genes.
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No-MI Control
6
23±2

Necropsy
parameters

n

Body weight (g)

d0 Control
No-MI Control
454±16
37 ± 1.9
3.7±0.12
2.3±0.14
1.05± 0.02

Table 1B

Echocardiography
parameters

Heart Rate (bpm)

Fractional shortening
(%)

EDD (mm)

ESD (mm)

PWTs (mm)

Echocardiography parameters

ND

% infarct area

8±0.9*

9±0.1*

5±0.2

Lung mass mg/ W
body weight (g)

0.87±0.03*

0.95±0.06*

0.74± 0.03

0.80±0.03*

0.81±0.04*

RV mass/ BW

15±0.4

16±0.3

16±0.7
0.71± 0.03

Tibia (mm)

Ratio-LV/BW:LV Tibia

34±2

31±1

Lung wt (dry; mg)
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490±18
10± 0.2*$
4.3 ± 0.1*$
3.8± 0.1*
0.53± 0.06*

7 ± 0.8*
4.5±0.12 *
4.2 ± 0.13*
0.56 ± 0.06*

Lipo-RvD1

day 1 MI

44 ± 2

473±18

MI-Saline

47 ± 1

30±1

146±16*

184±22*

127±8

Lung weight (mg)

17±1

19±1

17±2

Right ventricle (mg)

62±2*$

39 ± 2*

71 ± 3

Spleen weight (mg)

3.9±0.2*

3.2 ± 0.04

LV/BW (mg/g)

4.0 ± 0.24*

74±5

Left ventricle (mg)

76±4

19±0.5

8

Lipo-RvD1

day 1 MI

79±4 *

20±1

MI-Saline

d0 Control

Table 1A

0.40±0.06*

3.7±0.07*$

4.3±0.03*$

11 ±1.0*$

453±10

RvD1

53 ± 4

8±0.9*

0.96 ±0.04*

0.78 ±0.01*

16±0.3

32±2

176±17*

20±1

52 ± 4*$

3.8 ± 0.2*

72±5

20±1

8

RvD1

0.47 ± 0.05*

6.1 ± 0.18*

6.5±0.02*

5 ± 0.4*

491±16

MI-Saline

49 ± 1

18±0.7*

0.93±0.11*

0.81±0.03*

0.55± 0.05*$

3.6 ±0.08*$

3.8±0.12 *$

19± 0.5*$

479±15

Lipo-Rvd1

day 5 MI

55 ± 4

6±0.4$

0.91±0.09*

0.79±0.02*

16±0.5

28±1$

42±2*
17±0.2

119±8$

19±2

66±6$

3.8±0.3*$

77±7$

20±1

3

Lipo-Rvd1

211±12*

19±2

82 ± 5*

5.3 ± 0.31*

108±5*

21±1

6

MI-Saline

day 5 MI

0.54±0.05*$

3.5±0.2*$

4.1±0.1*$

15±2*$

466±18

RvD1

46 ± 2

7±0.5$

0.83±0.03*

0.80 ±0.02*

16±0.1

27±1$

136±10$

17±1

66 ± 6 $

3.6±0 .2*$

78±4$

20±0.5

8

RvD1
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Necropsy and echocardiography parameters in controls and post-MI RvD1 injected mice.
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p<0.05 vs MI-saline at respective time point

$

p<0.05 vs day 0 control;

*

Values are mean± SEM; n indicates sample size. LV, left ventricle; BW, body weight; bpm, beats per minute; EDD, end-diastolic dimension; ESD, end-systolic dimension; FS, fractional shortening; PWT,
Infarcted wall thickness, S,systole; mm, millimeter
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